Morgan Stanley Erasca, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Erasca, Inc. stock. As of the latest transaction made, Morgan Stanley holds 658,225 shares of ERAS stock, worth $1.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

658,225

Previous 691,814 4.86%

Holding current value

$1.43 Million

Previous $1.47 Million 8.01%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.67 - $2.55 $56,093 - $85,651	-33,589 Reduced 4.86%	658,225 $1.36 Million
Q4 2023 Feb 13, 2024	SELL	$1.67 - $2.49 $94,924 - $141,534	-56,841 Reduced 7.59%	691,814 $1.47 Million
Q3 2023 Nov 15, 2023	SELL	$1.97 - $2.91 $543,680 - $803,101	-275,980 Reduced 26.93%	748,655 $1.47 Million
Q2 2023 Aug 14, 2023	BUY	$2.57 - $3.3 $1.44 Million - $1.85 Million	560,260 Added 120.65%	1,024,635 $2.83 Million
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $306,523 - $496,702	111,870 Added 31.74%	464,375 $1.4 Million

Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $571,713 - $1.26 Million	146,970 Added 71.51%	352,505 $1.52 Million
Q3 2022 Nov 14, 2022	BUY	$5.82 - $10.68 $68,181 - $125,116	11,715 Added 6.04%	205,535 $1.6 Million
Q2 2022 Oct 27, 2022	BUY	$4.58 - $8.72 $755,539 - $1.44 Million	164,965 Added 571.7%	193,820 $1.08 Million
Q2 2022 Aug 15, 2022	BUY	$4.58 - $8.72 $755,539 - $1.44 Million	164,965 Added 571.7%	193,820 $1.08 Million
Q1 2022 Oct 27, 2022	SELL	$8.6 - $15.48 $1.42 Million - $2.55 Million	-164,965 Reduced 85.11%	28,855 $249,000
Q1 2022 May 13, 2022	BUY	$8.6 - $15.48 $1,840 - $3,312	214 Added 0.75%	28,855 $249,000
Q4 2021 Feb 14, 2022	BUY	$12.51 - $22.75 $316,965 - $576,416	25,337 Added 766.86%	28,641 $446,000
Q3 2021 Nov 15, 2021	BUY	$17.43 - $24.34 $57,588 - $80,419	3,304 New	3,304 $70,000

Others Institutions Holding ERAS

# of Institutions

117

Shares Held

74.3M

Call Options Held

7.1K

Put Options Held

40.1K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $266M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account